Non-invasive Monitoring of Sorafenib Effects on Tumor Growth and Angiogenesis by Dynamic Contrast-Enhanced CT Scans and Immunohistological Correlations

E. Bettina F. Schwarz, Clemens C. Cyran, Philipp M. Paprottka, S. Sourbron, Jobst Von Einem, Rabea Hinkel, Oliver Dietrich, Bernd Wintersberger, Konstantin Nikolaou, Maximilian F. Reiser, Karl-Walter Jauch & Christiane J. Bruns
Introduction: Inhibiting tumor growth and angiogenesis, the oral multikinase inhibitor sorafenib is used for the treatment of advanced HCC and RCC. Despite promising clinical results, there is no sufficient data on its anti-angiogenic, anti-proliferative and pro-apoptotic effects concerning (pre-) clinical[for full text, please go to the a.m. URL]